Obesity-enriched gut microbe degrades myo-inositol and promotes lipid absorption
- PMID: 38996548
- DOI: 10.1016/j.chom.2024.06.012
Obesity-enriched gut microbe degrades myo-inositol and promotes lipid absorption
Abstract
Numerous studies have reported critical roles for the gut microbiota in obesity. However, the specific microbes that causally contribute to obesity and the underlying mechanisms remain undetermined. Here, we conducted shotgun metagenomic sequencing in a Chinese cohort of 631 obese subjects and 374 normal-weight controls and identified a Megamonas-dominated, enterotype-like cluster enriched in obese subjects. Among this cohort, the presence of Megamonas and polygenic risk exhibited an additive impact on obesity. Megamonas rupellensis possessed genes for myo-inositol degradation, as demonstrated in vitro and in vivo, and the addition of myo-inositol effectively inhibited fatty acid absorption in intestinal organoids. Furthermore, mice colonized with M. rupellensis or E. coli heterologously expressing the myo-inositol-degrading iolG gene exhibited enhanced intestinal lipid absorption, thereby leading to obesity. Altogether, our findings uncover roles for M. rupellensis as a myo-inositol degrader that enhances lipid absorption and obesity, suggesting potential strategies for future obesity management.
Keywords: Megamonas; Megamonas rupellensis; Obesity; enterotype; genetics; gut microbiome; lipid absorption; myo-inositol; obesogenic microbe; polygenic risk.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Similar articles
-
The relationship of Megamonas species with nonalcoholic fatty liver disease in children and adolescents revealed by metagenomics of gut microbiota.Sci Rep. 2022 Dec 20;12(1):22001. doi: 10.1038/s41598-022-25140-2. Sci Rep. 2022. PMID: 36539432 Free PMC article.
-
Fatty acid overproduction by gut commensal microbiota exacerbates obesity.Cell Metab. 2023 Feb 7;35(2):361-375.e9. doi: 10.1016/j.cmet.2022.12.013. Epub 2023 Jan 17. Cell Metab. 2023. PMID: 36652945
-
Abnormalities in myo-inositol metabolism associated with type 2 diabetes in mice fed a high-fat diet: benefits of a dietary myo-inositol supplementation.Br J Nutr. 2015 Jun 28;113(12):1862-75. doi: 10.1017/S000711451500121X. Epub 2015 May 20. Br J Nutr. 2015. PMID: 25990651
-
Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies.Int J Mol Sci. 2021 Jun 24;22(13):6796. doi: 10.3390/ijms22136796. Int J Mol Sci. 2021. PMID: 34202683 Free PMC article. Review.
-
Production of myo-inositol: Recent advance and prospective.Biotechnol Appl Biochem. 2022 Jun;69(3):1101-1111. doi: 10.1002/bab.2181. Epub 2021 May 21. Biotechnol Appl Biochem. 2022. PMID: 33977572 Review.
Cited by
-
The Effectiveness and Safety of a Nutraceutical Combination in Overweight Patients with Metabolic Syndrome.Nutrients. 2024 Nov 21;16(23):3977. doi: 10.3390/nu16233977. Nutrients. 2024. PMID: 39683371 Free PMC article.
-
Towards Improved Bioavailability of Cereal Inositol Phosphates, Myo-Inositol and Phenolic Acids.Molecules. 2025 Feb 1;30(3):652. doi: 10.3390/molecules30030652. Molecules. 2025. PMID: 39942756 Free PMC article. Review.
-
Fecal microbiota transplantation improves Sansui duck growth performance by balancing the cecal microbiome.Sci Rep. 2025 Jul 1;15(1):22403. doi: 10.1038/s41598-025-04942-0. Sci Rep. 2025. PMID: 40593020 Free PMC article.
-
Acylated Ghrelin Mediates the Link Between Akkermansia Abundance and Insulin Resistance in Type 2 Diabetes.J Diabetes Res. 2025 Aug 5;2025:4051518. doi: 10.1155/jdr/4051518. eCollection 2025. J Diabetes Res. 2025. PMID: 40799671 Free PMC article.
-
Long-term weight change patterns in American adulthood in relation to gallstones: evidence from NHANES.BMC Gastroenterol. 2025 Apr 12;25(1):250. doi: 10.1186/s12876-025-03846-7. BMC Gastroenterol. 2025. PMID: 40221662 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical